Our in vivo results also suggested that the loss of 4.1N could aggravate the peritoneal dissemination of EOC cells; single-agent and combination therapies with a ROCK inhibitor and a 14-3-3 antagonist successfully reduced tumor growth. Here, YWHAQ is linked to neoplasm.